Latest Breaking News On - Ascendis pharma - Page 4 : comparemela.com

Morgan Stanley Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $140 00

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price hoisted by Morgan Stanley from $116.00 to $140.00 in a research note issued to investors on Thursday, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock. Other research analysts have also recently issued research reports about the stock. […]

Ascendis pharmaMirae asset global investments coRaymond james financial services advisors incJpmorgan chase coWells fargo companyJennison associatesGilbert cook incMorgan stanleyFree reportWells fargoModerate buyJames financial services advisorsAsset global investmentsDuality advisersGet free report

Weekly Research Analysts Ratings Updates for Ascendis Pharma A/S (ASND)

Several analysts have recently updated their ratings and price targets for Ascendis Pharma A/S (NASDAQ: ASND): 5/16/2024 – Ascendis Pharma A/S had its price target raised by analysts at Morgan Stanley from $116.00 to $140.00. They now have an “equal weight” rating on the stock. 5/15/2024 – Ascendis Pharma A/S was downgraded by analysts at […]

United statesAscendis pharmaCapital international investorsJpmorgan chase coMorgan stanleyMassachusetts financial services coWestfield capital management coPricet rowe associates incCantor fitzgeraldWells fargo companyAvoro capital advisorsWells fargoCapital managementCapital advisorsInternational investorsMassachusetts financial services

Rx Rundown: Sanofi, Bayer, Sands Capital and more

Rx Rundown: Sanofi, Bayer, Sands Capital and more
mmm-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mmm-online.com Daily Mail and Mail on Sunday newspapers.

United statesAscendis pharmaEli lillyReneo pharmaUniquity bioBrixton biosciencesEnveric biosciencesAcinonyx bioNabla bioCindome pharmaCardurion pharmaceuticalsBain capital life sciencesGilgamesh pharmaceuticalsBlood centers of americaCue healthBristol myers squibb

FDA Extends Review Period for Hypoparathyroidism Treatment TransCon PTH

FDA Extends Review Period for Hypoparathyroidism Treatment TransCon PTH
endocrinologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from endocrinologyadvisor.com Daily Mail and Mail on Sunday newspapers.

United statesJan mikkelsenAscendis pharmaDrug administrationAccess programNew drug applicationComplete response letterPrescription drug user fee actExpanded access program

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $140 00 by Analysts at Morgan Stanley

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $140 00 by Analysts at Morgan Stanley
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Ascendis pharmaMirae asset global investments coFinancial services group incQuadrant capital groupCantor fitzgeraldMorgan stanleyWells fargo companyEversource wealth advisorsAscendis pharmaas company profileFree reportModerate buySource wealth advisorsCapital groupServices groupMirae asset global investmentsAsset global investments